Steel
Build Your Comparison
Side-by-side financial analysisStock Comparison
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Steel
Aluminum
Drug Manufacturers - General
Packaging & Containers
Banks - Diversified
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Steel | Steel | Aluminum | Drug Manufacturers - General | Packaging & Containers | Banks - Diversified |
| Market Cap | $127M | $533M | $3.09B | $292.07B | $1.56B | $896.00B |
| Revenue (TTM) | $77M | $1.90B | $3.70B | $56.05B | $868M | $280.33B |
| Net Income (TTM) | $1M | $14M | $153M | $13.53B | $909M | $57.05B |
| Gross Margin | 21.8% | 82.8% | 10.2% | 75.3% | 22.8% | 60.0% |
| Operating Margin | -9.8% | 1.9% | 6.6% | 30.5% | 6.2% | 25.9% |
| Forward P/E | 16.9x | 20.7x | 18.5x | 17.5x | 24.7x | 14.4x |
| Total Debt | $13M | $313M | $1.12B | $37.03B | $505M | $942.38B |
| Cash & Equiv. | $58M | $12M | $7M | $11.44B | $30M | $343.34B |
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Ascent Industries C… (ACNT) | 100 | 187.8 | +87.8% |
| Olympic Steel, Inc. (ZEUS) | 100 | 409.3 | +309.3% |
| Kaiser Aluminum Cor… (KALU) | 100 | 258.9 | +158.9% |
| Novartis AG (NVS) | 100 | 185.2 | +85.2% |
| TriMas Corporation (TRS) | 100 | 172.5 | +72.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACNT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.47, Low D/E 15.3%, current ratio 6.72x
ZEUS is the clearest fit if your priority is valuation efficiency.
- PEG 0.49 vs NVS's 1.14
KALU has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 11.5%, EPS growth 135.9%, 3Y rev CAGR -0.5%
- 11.5% revenue growth vs ACNT's -57.9%
- +148.9% vs ACNT's +10.2%
NVS is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 1 yrs, beta 0.45, yield 2.6%
- Beta 0.45, yield 2.6%, current ratio 1.12x
- Beta 0.45 vs KALU's 1.86, lower leverage
- 2.6% yield, 1-year raise streak, vs JPM's 1.9%, (1 stock pays no dividend)
TRS ranks third and is worth considering specifically for quality and efficiency.
- 104.7% margin vs ZEUS's 0.7%
- 54.6% ROA vs ACNT's 1.1%, ROIC 0.9% vs -6.6%
JPM is the clearest fit if your priority is long-term compounding.
- 465.8% 10Y total return vs NVS's 187.2%
- Lower P/E (14.4x vs 24.7x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.5% revenue growth vs ACNT's -57.9% | |
| Value | Lower P/E (14.4x vs 24.7x) | |
| Quality / Margins | 104.7% margin vs ZEUS's 0.7% | |
| Stability / Safety | Beta 0.45 vs KALU's 1.86, lower leverage | |
| Dividends | 2.6% yield, 1-year raise streak, vs JPM's 1.9%, (1 stock pays no dividend) | |
| Momentum (1Y) | +148.9% vs ACNT's +10.2% | |
| Efficiency (ROA) | 54.6% ROA vs ACNT's 1.1%, ROIC 0.9% vs -6.6% |
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TRS leads in 1 of 6 categories
ZEUS leads 1 • KALU leads 1 • ACNT leads 0 • NVS leads 0 • JPM leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
TRS leads this category, winning 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 3663.4x ACNT's $77M. TRS is the more profitable business, keeping 104.7% of every revenue dollar as net income compared to ZEUS's 0.7%. On growth, KALU holds the edge at +42.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $77M | $1.9B | $3.7B | $56.1B | $868M | $280.3B |
| EBITDAEarnings before interest/tax | -$3M | $45M | $368M | $22.5B | $112M | $81.4B |
| Net IncomeAfter-tax profit | $1M | $14M | $153M | $13.5B | $909M | $57.0B |
| Free Cash FlowCash after capex | -$7M | $42M | $24M | $16.4B | $48M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +21.8% | +82.8% | +10.2% | +75.3% | +22.8% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -9.8% | +1.9% | +6.6% | +30.5% | +6.2% | +25.9% |
| Net MarginNet income ÷ Revenue | +1.6% | +0.7% | +4.1% | +24.1% | +104.7% | +20.4% |
| FCF MarginFCF ÷ Revenue | -9.0% | +2.2% | +0.7% | +29.2% | +5.6% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.9% | +4.4% | +42.4% | -0.7% | -30.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +8.7% | -21.7% | +183.2% | -9.3% | +70.3% | +16.0% |
Valuation Metrics
ZEUS leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 14.0x trailing earnings, TRS trades at a 50% valuation discount to KALU's 28.2x P/E. Adjusting for growth (PEG ratio), ZEUS offers better value at 0.58x vs NVS's 1.39x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $127M | $533M | $3.1B | $292.1B | $1.6B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $83M | $834M | $4.2B | $317.7B | $2.0B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -24.22x | 24.29x | 28.16x | 21.29x | 14.01x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.93x | 20.72x | 18.54x | 17.52x | 24.70x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.58x | 0.93x | 1.39x | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | 10.59x | 13.43x | 14.17x | 28.57x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 1.69x | 0.27x | 0.92x | 5.33x | 2.41x | 3.20x |
| Price / BookPrice ÷ Book value/share | 1.56x | 0.97x | 3.84x | 6.43x | 2.39x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | 127.14x | — | 16.51x | 22.52x | 8.88x |
Profitability & Efficiency
Evenly matched — ACNT and NVS each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
TRS delivers a 101.1% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $1 for ACNT. ACNT carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), ACNT scores 6/9 vs JPM's 5/9, reflecting solid financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +1.4% | +2.4% | +18.7% | +31.4% | +101.1% | +15.9% |
| ROA (TTM)Return on assets | +1.1% | +1.3% | +5.9% | +12.1% | +54.6% | +1.3% |
| ROICReturn on invested capital | -6.6% | +4.3% | +7.8% | +18.8% | +0.9% | +4.5% |
| ROCEReturn on capital employed | -6.0% | +5.6% | +9.4% | +21.1% | +1.1% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 6 | 6 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.15x | 0.55x | 1.36x | 0.80x | 0.72x | 2.60x |
| Net DebtTotal debt minus cash | -$44M | $301M | $1.1B | $25.6B | $475M | $599.0B |
| Cash & Equiv.Liquid assets | $58M | $12M | $7M | $11.4B | $30M | $343.3B |
| Total DebtShort + long-term debt | $13M | $313M | $1.1B | $37.0B | $505M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 2.15x | 4.84x | 13.92x | 2.87x | 0.74x |
Total Returns (Dividends Reinvested)
KALU leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $12,545 for ACNT. Over the past 12 months, KALU leads with a +148.9% total return vs ACNT's +10.2%. The 3-year compound annual growth rate (CAGR) favors KALU at 42.3% vs ZEUS's 1.8% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.5% | +9.1% | +59.7% | +13.9% | +14.1% | -0.5% |
| 1-Year ReturnPast 12 months | +10.2% | +54.9% | +148.9% | +30.7% | +51.7% | +21.8% |
| 3-Year ReturnCumulative with dividends | +41.3% | +5.4% | +188.2% | +74.4% | +52.0% | +138.2% |
| 5-Year ReturnCumulative with dividends | +25.4% | +52.1% | +60.3% | +94.0% | +33.0% | +118.2% |
| 10-Year ReturnCumulative with dividends | +93.7% | +96.3% | +153.5% | +187.2% | +151.7% | +465.8% |
| CAGR (3Y)Annualised 3-year return | +12.2% | +1.8% | +42.3% | +20.4% | +15.0% | +33.6% |
Risk & Volatility
Evenly matched — KALU and NVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
NVS is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than KALU's 1.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KALU currently trades 98.0% from its 52-week high vs ACNT's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.47x | 1.23x | 1.86x | 0.45x | 1.09x | 0.94x |
| 52-Week HighHighest price in past year | $17.92 | $52.65 | $194.43 | $170.46 | $43.72 | $337.25 |
| 52-Week LowLowest price in past year | $11.62 | $27.11 | $71.44 | $112.34 | $26.16 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +90.9% | +98.0% | +89.8% | +94.5% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 48.2 | 59.6 | 59.8 | 57.8 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 73K | 47 | 233K | 1.4M | 400K | 7.0M |
Analyst Outlook
Evenly matched — NVS and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACNT as "Buy", ZEUS as "Buy", KALU as "Hold", NVS as "Hold", TRS as "Buy", JPM as "Buy". Consensus price targets imply 28.1% upside for ACNT (target: $18) vs -14.3% for ZEUS (target: $41). For income investors, NVS offers the higher dividend yield at 2.63% vs TRS's 0.39%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $41.00 | $165.33 | $170.00 | $38.00 | $339.75 |
| # AnalystsCovering analysts | 4 | 6 | 22 | 25 | 14 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | +1.2% | +1.6% | +2.6% | +0.4% | +1.9% |
| Dividend StreakConsecutive years of raises | 1 | 4 | 0 | 1 | 0 | 15 |
| Dividend / ShareAnnual DPS | — | $0.57 | $3.09 | $4.02 | $0.16 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +7.2% | 0.0% | 0.0% | +3.2% | +6.6% | +3.9% |
TRS leads in 1 of 6 categories (Income & Cash Flow). ZEUS leads in 1 (Valuation Metrics). 3 tied.
ACNT vs ZEUS vs KALU vs NVS vs TRS vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ACNT or ZEUS or KALU or NVS or TRS or JPM a better buy right now?
For growth investors, Kaiser Aluminum Corporation (KALU) is the stronger pick with 11.
5% revenue growth year-over-year, versus -57. 9% for Ascent Industries Co. (ACNT). TriMas Corporation (TRS) offers the better valuation at 14. 0x trailing P/E (24. 7x forward), making it the more compelling value choice. Analysts rate Ascent Industries Co. (ACNT) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ACNT or ZEUS or KALU or NVS or TRS or JPM?
On trailing P/E, TriMas Corporation (TRS) is the cheapest at 14.
0x versus Kaiser Aluminum Corporation at 28. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Olympic Steel, Inc. wins at 0. 49x versus Novartis AG's 1. 14x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ACNT or ZEUS or KALU or NVS or TRS or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to +25. 4% for Ascent Industries Co. (ACNT). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ACNT's +93. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ACNT or ZEUS or KALU or NVS or TRS or JPM?
By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.
45β versus Kaiser Aluminum Corporation's 1. 86β — meaning KALU is approximately 311% more volatile than NVS relative to the S&P 500. On balance sheet safety, Ascent Industries Co. (ACNT) carries a lower debt/equity ratio of 15% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ACNT or ZEUS or KALU or NVS or TRS or JPM?
By revenue growth (latest reported year), Kaiser Aluminum Corporation (KALU) is pulling ahead at 11.
5% versus -57. 9% for Ascent Industries Co. (ACNT). On earnings-per-share growth, the picture is similar: TriMas Corporation grew EPS 400. 0% year-over-year, compared to -48. 8% for Olympic Steel, Inc.. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ACNT or ZEUS or KALU or NVS or TRS or JPM?
Novartis AG (NVS) is the more profitable company, earning 25.
6% net margin versus -7. 5% for Ascent Industries Co. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -9. 0% for ACNT. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ACNT or ZEUS or KALU or NVS or TRS or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Olympic Steel, Inc. (ZEUS) is the more undervalued stock at a PEG of 0. 49x versus Novartis AG's 1. 14x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 24. 7x for TriMas Corporation — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACNT: 28. 1% to $18. 00.
08Which pays a better dividend — ACNT or ZEUS or KALU or NVS or TRS or JPM?
In this comparison, NVS (2.
6% yield), JPM (1. 9% yield), KALU (1. 6% yield), ZEUS (1. 2% yield), TRS (0. 4% yield) pay a dividend. ACNT does not pay a meaningful dividend and should not be held primarily for income.
09Is ACNT or ZEUS or KALU or NVS or TRS or JPM better for a retirement portfolio?
For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
45), 2. 6% yield, +187. 2% 10Y return). Kaiser Aluminum Corporation (KALU) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +187. 2%, KALU: +153. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ACNT and ZEUS and KALU and NVS and TRS and JPM?
These companies operate in different sectors (ACNT (Basic Materials) and ZEUS (Basic Materials) and KALU (Basic Materials) and NVS (Healthcare) and TRS (Consumer Cyclical) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACNT is a small-cap quality compounder stock; ZEUS is a small-cap quality compounder stock; KALU is a small-cap quality compounder stock; NVS is a large-cap quality compounder stock; TRS is a small-cap deep-value stock; JPM is a large-cap deep-value stock. ZEUS, KALU, NVS, JPM pay a dividend while ACNT, TRS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.